National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Teduglutide (Revestive®) is indicated for the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation.

NCPE Assessment Process Ongoing
Rapid review received 13/03/2017
Rapid review completed 12/04/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 12/04/2017
Pre-submission consultation with applicant 15/05/2017
Submission received from applicant 31/07/2017
Current status NCPE assessment ongoing